Trial Condition(s):
Open, multicentric, prospective, quality of life Study in Multiple Sclerosis patients
14168
Not Available
Not Available
To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event
: - Males or females aged 18 years or over, having received a confirmed diagnosis of RRMS as defined by the MacDonald or Poser criteria or after a first clinical demyelinating event suggestive of Multiple Sclerosis, and meeting the requirements of the study inclusion criteria - The choice of treatment must be clearly dissociated from the decision to include the patient in the study.
No Exclusion Criteria Available
Locations | |
---|---|
Locations Investigative Site Many Locations, France | Contact Us: E-mail: [email protected] Phone: Not Available |
Prospective multicenter, non-interventional study to evaluate the impact of the introduction of interferon beta-1 b treatment on daily life activities in patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event or having received a confirmed diagnosis of RRMS
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1